Literature DB >> 36005758

Lab-Attenuated Rabies Virus Facilitates Opening of the Blood-Brain Barrier by Inducing Matrix Metallopeptidase 8.

An Fang1,2, Yueming Yuan1,2, Fei Huang1,2, Caiqian Wang1,2, Dayong Tian1,2, Rui Zhou1,2, Ming Zhou1,2, Huanchun Chen1,2, Zhen F Fu1,2, Ling Zhao1,2.   

Abstract

Infection with laboratory-attenuated rabies virus (RABV), but not wild-type (wt) RABV, can enhance the permeability of the blood-brain barrier (BBB), which is considered a key determinant for RABV pathogenicity. A previous study showed that the enhancement of BBB permeability is directly due not to RABV infection but to virus-induced inflammatory molecules. In this study, the effect of the matrix metallopeptidase (MMP) family on the permeability of the BBB during RABV infection was evaluated. We found that the expression level of MMP8 was upregulated in mice infected with lab-attenuated RABV but not with wt RABV. Lab-attenuated RABV rather than wt RABV activates inflammatory signaling pathways mediated by the nuclear factor κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. Activated NF-κB (p65) and AP-1 (c-Fos) bind to the MMP8 promoter, resulting in upregulation of its transcription. Analysis of mouse brains infected with the recombinant RABV expressing MMP8 indicated that MMP8 enhanced BBB permeability, leading to infiltration of inflammatory cells into the central nervous system (CNS). In brain-derived endothelial cells, treatment with MMP8 recombinant protein caused the degradation of tight junction (TJ) proteins, and the application of an MMP8 inhibitor inhibited the degradation of TJ proteins after RABV infection. Furthermore, an in vivo experiment using an MMP8 inhibitor during RABV infection demonstrated that BBB opening was diminished. In summary, our data suggest that the infection of lab-attenuated RABV enhances the BBB opening by upregulating MMP8. IMPORTANCE The ability to change BBB permeability was associated with the pathogenicity of RABV. BBB permeability was enhanced by infection with lab-attenuated RABV instead of wt RABV, allowing immune cells to infiltrate into the CNS. We found that MMP8 plays an important role in enhancing BBB permeability by degradation of TJ proteins during RABV infection. Using an MMP8 selective inhibitor restores the reduction of TJ proteins. We reveal that MMP8 is upregulated via the MAPK and NF-κB inflammatory pathways, activated by lab-attenuated RABV infection but not wt RABV. Our findings suggest that MMP8 has a critical role in modulating the opening of the BBB during RABV infection, which provides fresh insight into developing effective therapeutics for rabies and infection with other neurotropic viruses.

Entities:  

Keywords:  blood-brain barrier; inflammation; matrix metallopeptidase 8; permeability change; rabies virus

Mesh:

Substances:

Year:  2022        PMID: 36005758      PMCID: PMC9472762          DOI: 10.1128/jvi.01050-22

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  64 in total

1.  Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system.

Authors:  Timothy W Phares; Rhonda B Kean; Tatiana Mikheeva; D Craig Hooper
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

2.  Matrix Metalloproteinase-8 Inhibition Prevents Disruption of Blood-Spinal Cord Barrier and Attenuates Inflammation in Rat Model of Spinal Cord Injury.

Authors:  Hemant Kumar; Min-Jae Jo; Hyemin Choi; Manjunatha S Muttigi; Seil Shon; Byung-Joo Kim; Soo-Hong Lee; In-Bo Han
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

3.  Overexpression of Interleukin-7 Extends the Humoral Immune Response Induced by Rabies Vaccination.

Authors:  Yingying Li; Ming Zhou; Zhaochen Luo; Yachun Zhang; Min Cui; Huanchun Chen; Zhen F Fu; Ling Zhao
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

4.  Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier.

Authors:  Hanna Gerwien; Sven Hermann; Xueli Zhang; Eva Korpos; Jian Song; Klaus Kopka; Andreas Faust; Christian Wenning; Catharina C Gross; Lisa Honold; Nico Melzer; Ghislain Opdenakker; Heinz Wiendl; Michael Schäfers; Lydia Sorokin
Journal:  Sci Transl Med       Date:  2016-11-09       Impact factor: 17.956

5.  Neisseria meningitidis induces brain microvascular endothelial cell detachment from the matrix and cleavage of occludin: a role for MMP-8.

Authors:  Alexandra Schubert-Unkmeir; Christian Konrad; Heiko Slanina; Florian Czapek; Sabrina Hebling; Matthias Frosch
Journal:  PLoS Pathog       Date:  2010-04-29       Impact factor: 6.823

6.  Potential role of MCP-1 in endothelial cell tight junction 'opening': signaling via Rho and Rho kinase.

Authors:  Svetlana M Stamatovic; Richard F Keep; Steven L Kunkel; Anuska V Andjelkovic
Journal:  J Cell Sci       Date:  2003-11-15       Impact factor: 5.285

7.  Matrix Metalloproteinase-12 Induces Blood-Brain Barrier Damage After Focal Cerebral Ischemia.

Authors:  Bharath Chelluboina; Jeffrey D Klopfenstein; David M Pinson; David Z Wang; Raghu Vemuganti; Krishna Kumar Veeravalli
Journal:  Stroke       Date:  2015-11-03       Impact factor: 7.914

8.  Intracerebral administration of recombinant rabies virus expressing GM-CSF prevents the development of rabies after infection with street virus.

Authors:  Hualei Wang; Guoqing Zhang; Yongjun Wen; Songtao Yang; Xianzhu Xia; Zhen F Fu
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

9.  Possible Mechanisms of Di(2-ethylhexyl) Phthalate-Induced MMP-2 and MMP-9 Expression in A7r5 Rat Vascular Smooth Muscle Cells.

Authors:  Mei-Fen Shih; Kuang-Hung Pan; Jong Yuh Cherng
Journal:  Int J Mol Sci       Date:  2015-12-04       Impact factor: 5.923

10.  Viral pathogen-associated molecular patterns regulate blood-brain barrier integrity via competing innate cytokine signals.

Authors:  Brian P Daniels; David W Holman; Lillian Cruz-Orengo; Harsha Jujjavarapu; Douglas M Durrant; Robyn S Klein
Journal:  MBio       Date:  2014-08-26       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.